Ribociclib With Letrozole vs Letrozole Alone in Elderly Patients With Hormone Receptor-Positive, HER2-negative Breast Cancer in the Randomized MONALEESA-2 Trial

Breast Cancer Research and Treatment - Netherlands
doi 10.1007/s10549-017-4523-y
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

TBCRC 002: A Phase II, Randomized, Open-Label Trial of Preoperative Letrozole With or Without Bevacizumab in Postmenopausal Women With Newly Diagnosed Stage 2/3 Hormone Receptor-Positive and HER2-negative Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
2020English

Palbociclib With Letrozole in Postmenopausal Women With ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA‐2 Trial

Oncologist
Cancer ResearchMedicineOncology
2019English

Cost-Effectiveness of Palbociclib Plus Letrozole Versus Letrozole Alone as a First-Line Treatment in Women With Oestrogen Receptor-Positive, HER2-negative, Advanced Breast Cancer. Revised Results for the Swiss Health Care Setting

Breast Cancer Research and Treatment
Cancer ResearchOncology
2017English

Is Letrozole Needed for Controlled Ovarian Stimulation in Patients With Estrogen Receptor-Positive Breast Cancer?

Gynecological Endocrinology
GynecologyEndocrinologyMetabolismObstetricsDiabetes
2013English

Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide as Primary Systemic Treatment in Elderly Breast Cancer Patients

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2006English

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

Clinical Cancer Research
Cancer ResearchOncology
2019English

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2019English

BCT Score Predicts Chemotherapy Benefit in Asian Patients With Hormone Receptor-Positive, HER2-negative, Lymph Node-Negative Breast Cancer

PLoS ONE
Multidisciplinary
2018English

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Geburtshilfe und Frauenheilkunde
GynecologyMidwiferyMaternityObstetrics
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy